

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-
tin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-
AUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular
Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of
Angiopietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. Nature 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab.

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.


30

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
 molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R₃ und R₄ a) each independently from each other have the meaning
 of lower alkyl,

9

b) together form a bridge of general partial formula II;




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G

20

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T

25

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one or more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.


25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranil acid derivatives of general formula IV

30

11



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group


20



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/or R _a and/or R _b together with R _c and/or R _d or R _e together with R _e and/or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
15		
	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
20		
	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy,
25		
	R ⁴ , R ⁵ , R ⁶ and R ⁷	independently from each other have the meaning of hydrogen, halogen or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or

13


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.


10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.


More preferentially compounds of general formula V




- 15 in which
R¹ has the meaning of group

20






in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is $-\text{CH}_3$, fluoro,
chloro or $-\text{CF}_3$

in which R^4 is fluoro,
chloro, bromo, $-\text{CF}_3$,
 $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or
 $-\text{CH}_2\text{OH}$

in which R^6 is
 $-\text{CH}_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts can be used as compound I or II in the inventive pharmaceutical
composition.

These compounds have the same properties as already mentioned above under
compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in
combination.

The above mentioned compounds are also claimed matter within the inventive
combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences
coding for such peptides, which are used for the treatment of angiogeneous
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of
main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.
For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.
If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.
These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
- 30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the
- 15 tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of
5 the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of
10 intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a

10 reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of
 20 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of
 targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex
 via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor
 system by means of the VEGF receptor tyrosine kinase inhibitor (4-
 30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate
 over separate modes of intervention (treatment modes of groups 1-4 are given in
 Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS


1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 10 2. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of
- g) compounds which inhibit receptor tyrosine kinase activity,
 - h) compounds which inhibit ligand binding to receptors,
 - 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.
- 20 13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a
- 25 14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.
- 30 15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,


25 whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

30

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV

5



in which

A

has the meaning of group $=NR^2$,

10


W

has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R⁴, R⁵, R⁶ and R⁷


substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R⁵ and R⁶ together form the group



R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts,


and/ or a compound of general formula V



V,


in which

R¹ has the meaning of group




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,



in which R^8 is -CH₃, fluoro, chloro or -CF₃


in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1

Best Available Copy




Fig. 2




Fig. 3




Fig. 4

Best Available Copy




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEP M1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

35

40

45

50

55

```
ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctcttttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaaaaaac cataatgggtg ccacagggat ggagcagggg agggcatctc 300
taacgtgtcc tctagtctat ctctgctaaa cagaaccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgtg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaacgca acctaacca agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgtctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cgggtttctta atgtccctgg tggcgggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcagggtggg ctgcatagc tcatttaatg ttaaagcga tcaggggcct ctctcccg 1320
ttctgccagg ggtttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtccg tctggctcgtc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgaccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtccac attcgtacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgttag gccgtgctgt ctggggctcg aggtctttc tgctggtgct 1620
cttggaaggc cgggtagtct tgctgcagag acaaagcatc tcccttccc ttccgggctg 1680
atgttggttc attcatatct acgccagagt ccaactggc atcattactt ccgttcctc 1740
ggctctttt gagaatcaat gtatgaatgt ctaacctgac cgttggaact gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct
```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctacccag 60
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct tttagcaatta gatgggagag aagggaata gtacttgaaa ttagggccct 540
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

tagagatgtt ggttgatgac ccccggtatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
 25 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcat tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420
 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480
 30 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

cccacaacac agggggcctg aaacacgcca gcctctctc tgtggtcagc ttggcccagt 60
 40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctgggtccg tgtaagggtc tgagaagggtg ccctgggtcg 180
 ggggtgctgc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
 gcaccaactc cagcaggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300
 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcaggggtg 360
 45 ctgctggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacataggtg cccatcagt 480
 ctccgcggtg cgcgaggcga ccattctctg ccaccgagat cttggccatc tgacgtctca 540
 cggccgcccag cgcccgtcc acctgtgggt ccttggccgg cagtgcgccg agctccccct 600
 cttctgccc cagccgtctt tctcgccgag acaggtaaat gacatggccc aggtagacca 660
 50 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
 aggcctgggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccaccca cggctgagtg ctctggacc tggccagca 900
 acttctccac gaagcccag tcacccatgg ctcccgggca tccgtcggca aggagacaga 960
 55 gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcaggag 1020
 gtctgccacg ccggttctac cgctgcctg ccgggcggcc cagggtggagg tggggacgat 1080
 ggcggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaa 60

	aaaaagtgt	ttttgaaaat	gttgaggttg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acaccccctt	ggttcgca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gccatggact	tccccgcctt	ggaatgtgtg	gtgaaaagt	gggccagggc	240
5	ccagacccaa	gaggagagg	tggtccgcag	acaccccg	atgtcagcat	ccccgcacct	300
	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgtctg	ggaacagggt	gcaggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatggtgc	caggacaggt	480
	gtcccttcag	tctcttggtt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
10	gttgtaacct	tcctgctctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
	atcatcattg	ttgctttatc	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctcccacgag	aatgccacag	gggcccgtgca	720
	ctgggacagg	ttctctgtag	aaccccagg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagctc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
15	accaaaggcc	tcctgttctg	ttatttcaac	taaatcaaca	tgctattttg	ttttcactca	900
	cttctgactt	tagcctcggt	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
	<211> 2313						
20	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctgggtggtg	agcagggacg	gtgcaccgga	cggcgggatc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcgggcggg	gggcagctct	cggggctgct	120
	ggtattacct	gcgctacttc	ttcctctctg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatgggtc	tatggcaacg	tgacgtgag	cacagagtcc	aacctgcagg	240
30	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggtcacg	gcctcccagt	300
	ccaacttgac	caaggagctc	aacttcacca	cccgcgcca	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tgcgcgcgac	ctggaccgca	tcaatgccag	cttcgcgcag	tgccagggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcttgcctc	ttcatgctga	540
	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgcactaagg	600
35	ataaggaaa	cgtgtgctg	aacaaacg	tgccggagga	acagctggtt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtgca	720
	agccctctgc	ctgcccctgg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
	ctcggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
40	ggtggaggag	ctggcccggg	gcctccgggc	ggatatcgaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tggaagccca	gcagggcctg	cgggccagtc	aggaggcgaa	1020
	acagaaggtg	gagaaggagg	ctcaggcccg	ggaggccaag	ctccaagctg	aatgctccc	1080
	gcagaccagc	ctagcgctgg	aggagaaggc	gggtctgcgg	aaggaaacgag	acaacctggc	1140
	caaggagctg	gaagagaaga	agagggaggg	ggagcagctc	aggatggagc	tggccatcag	1200
45	aaactcagcc	ctggacacct	gcataagac	caagtgcgag	ccgatgatgc	cagtgtcaag	1260
	gccccatggc	cctgtcccca	acccccagcc	catcgaccca	gctagcctgg	aggagttaa	1320
	gaggaagatc	ctggagtccc	agaggccccc	tgcaggcatc	cctgtagccc	catccagtgg	1380
	ctgaggaggg	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccgaggat	1440
	gcagggatat	gctcacagcg	cccagacaaa	ccccctccc	ccgcccccaa	ccaccagg	1500
50	ccaccatcag	acaactccct	gcatacaaac	ccctagtacc	ctctcacacc	cgcacccg	1560
	cctcacgac	cctcacccag	agcacacggc	cgcggagatg	acgtcacgca	agcaacggcg	1620
	ctgacgtcac	atatcacctg	gggtgatggc	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
55	tcacacagac	cgccgcatgg	catcacacag	acggtgatga	tgacacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatatggcac	caacatcaca	tgacgcatg	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacgggcca	aggtaccac	aggatcccat	ccccctccgc	acagccctgg	gccccagcac	2040
	ctcccctcct	ccagcttctc	ggcctcccag	ccacttctc	acccccagtg	cctggacccg	2100
60	gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtgttt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggggtc	cctgttgctg	ggaggggagc	cactccttct	2220
	cccccaactc	ccagccctgc	ctgtggcccg	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaatacct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210> 7						
	<211> 389						

<212> DNA
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatccctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcaccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgat atatttgtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8

15

<211> 157
<212> DNA
<213> Human

<400> 8

20

tgcttttaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaacgtga aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<400> 9

aatagtcaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatggttg acaaatctgt gtgttatttc ttttctacct 180
35 accatatttta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480
40 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

<210> 10

45

<211> 1508
<212> DNA
<213> Human

<400> 10

50

cacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggctc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaatct 240
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgc cctaccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcgccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtctgaca acccatgttc ttgcagccag tctcactgtt gtacacgat gtcagccatg 540
ggtgtcatgt ccctcttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaaagt tcccactgtc ccccctagga actttgaaaa accaactag 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactttgg cactgttaat agaaagttag gatagctttt 840
gctgttttgcg gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctcagctaata ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtac ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatattttt 1080
 gtatatataa taatatattgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgttgtacat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 10 ttcattgtata ttgtacagtt acagtataat tcaaccttta ttttctaatt ttttcaacat 1320
 attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 20 gggcaggtga tcagggcaca catttcccggt ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccagc 120
 aggatgggtg gccagctgta agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acattttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagtttttg 360
 25 acctcggccg cgaccacgct gggtagcga
 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 35 tttttttttt ttggattgca aaaatttatt aaaattggag aactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggctgagg atcacttgag 120
 ccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatatataat caggggcaaaa taaaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360
 40 cattacatca ttggttacac tgaatatcat cacatgtacc aaaagctgac tcacctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcccta 480
 ctcaatttcc ttctcagta ctttttaact tttaaacagc taatcactcc catctacaga 540
 ttaaagggtga tatgccacca aaaccttttg ccaccttaa aatttccttc aaagttttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 45 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 taccaggagc agaaccatta agctgggtcca ggcaagtgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taagggtgcta tccagagcca 900
 cactgcatct gcacccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960
 50 ataagagttc ttttgatgac g
 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctggggacctc tgggtaggc aactgccc 120
 tcttcccccc agagcgaccc ccggggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggtcatca cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t
 <210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagttgttg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
 10 tttgaaaatg ttaaatacaa gtcctattct ctttgtccag ctggggttag cttagaggtag 180
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaaagc caagttaact 240
 gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgttgtatct 300
 taaaagtcatt ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
 15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
 tactgaaaaa aatgggtgcca tatgtccaa agacatttcc ccaagataac tgccaaagag 540
 tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
 attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660
 actacgaaca tgagagtaca agaggaaaact ttcataatgc attttttcat tcatacatc 720
 attcaataaa cattagccaa gctaattgtcc caagccactg tgccagggtat taacaatata 780
 20 acaacaataa aagacacagt ccttcctctc aagggtttca gtctagtagg gaagatgatt 840
 attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
 gcctatgttc tcagatattc tgggttaggtc aggagtggga acccaaaatc aattccttta 960
 acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

cgaggtgggc caccctgtgc tgggtctgaga tttttaaatg aggattacat tatectattt 60
 ataataattcc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
 35 aactgtatta tgactctcaa tatttaaaca tttaaaaaaa tgttagtggt tgttaagcac 240
 caatcttaac tatttcacct gcccgggcgg ccgctcgagg

40 <210> 16
 <211> 2041
 <212> DNA
 <213> Human

<400> 16

45 cccccgcag aactcccccc tggaatagga tttttaaac ccttgacaat tagaaatcct 60
 atagaggtta gcatctttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
 cttaaaacca attcagcaca tatgtataaa gaacctttt taaaaacatt tgtacttgaa 180
 atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
 50 aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
 ttacctctag catcaattct tttataaaga atgctaataa aattacattt tttgttcagt 420
 aaaaactgaag atagaccatt taaatgcttc taccaaaatt aacgcagctt aattagggac 480
 caggtaacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
 gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
 55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
 tagatatttg ttatagctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720
 gcatttttga ctctctcagg atcaaaatac gagtctgcca actgtattaa atcctctctc 780
 accccctcca ccagttggtc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
 ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
 60 ttctctgtaa tatagtttat tgtcttttgg tatagcatcc ataagttctt tctgtagagg 960
 tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
 atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
 ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
 ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200
 65 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtgtac atctgatatg 1260
 aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtccc	tgaaggcttt	aatttttttag	caagggtctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
5	ccaaaaccag	tggccagtg	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggatttcag	gttcctccgt	gatttgcata	1620
	gttttctcag	cattttgcag	agaggcacag	ttttcacaat	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggt	tggtttcacc	1740
	tccccggttt	tgaggatcat	ctttattaac	adagaatctt	ttagattcgt	tagggacaga	1800
10	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggttttt	cattcacaag	1860
	tgagtcacag	atgaaggcag	ctgttggttg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcat	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaaacgca	agcgaagat	ctgtaaaggc	2040
	t						
15	<210>	17					
	<211>	235					
	<212>	DNA					
	<213>	Human					
20	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccctc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaacaa	ctgtagtctc	120
25	agatactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aaggttacag	180
	tgggccacga	tcattgtcatt	acactccagc	ttgggtgaca	aatagagact	gtcta	
	<210>	18					
	<211>	2732					
	<212>	DNA					
30	<213>	Human					
	<400>	18					
35	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttctgtggt	60
	tcattgtgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttgggtg	tcacattgtg	caaaatgggtg	aagcattcaa	acactttgaa	180
	accagattct	agcaggttgg	aaaacattaa	gtcttgggtg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtcctttgg	gttgcttttt	attaatgagg	agactattgt	300
40	gatggcatat	ctcttcaact	tatttaattgc	tttccaggga	gtgttcattt	tcattctttca	360
	ctgtgctctc	caaaagaaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcactactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctcg	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
45	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
	catcttcaag	atattatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgctg	cacaagggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggaagaaga	cctctctccc	tccaggagga	1260
55	gtgagaatga	ggacatttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatggtta	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctgggt	acaagtcttt	1440
	aatcatacag	ctaaggaatt	ccaagggcca	catgagagta	ttataaaata	aagacaccat	1500
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tgggtgtaaa	aagatgactg	aaccttgcat	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattatttgt	tacaaagaaa	agagatgcca	1680
	gccaggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	ttttagggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgcagttc	actgcaaatc	ttttacatta	aggcaaaagt	tgaaaacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatattttg	ttctattgct	agggtaaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgctattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgacacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcat	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattacttac	attttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgctaccctt	gtttattctt	gaacagaggg	caaagagggc	actgggcact	tctcacaaac	2460
	tttctagtga	acaaaagggtg	cctatttctt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
10	actcttccat	attccttctg	cctatatatta	gtaatttaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gccatccact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210>	19					
	<211>	276					
	<212>	DNA					
	<213>	Human					
20	<400>	19					
	ctccctaaat	gattttaaaa	taaattggat	aaacatatga	tataaagtgg	gtactttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccctata	120
	tattccctat	atagcaaaac	aaaaccagga	cctcccaact	gcatgcctca	agtccctgtg	180
25	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaataccctg	gccgcgacca	cgctgg			
	<210>	20					
	<211>	2361					
30	<212>	DNA					
	<213>	Human					
	<400>	20					
35	attgtaccag	ccttgatgaa	cgtggggcct	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcacccg	tctttgagga	tgtagtggat	gtgcttctg	240
	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
40	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaagag	ccagcatctg	gacagtgatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggtc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagttgga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccacc	600
45	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaaagt	cactttgatg	tggagacagc	catcaagggtc	ctccggcagg	720
	ctggctacta	ctcccattg	ctgtatctgg	cggagaacca	tgcatatcat	gagtgtgacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggaagc	840
	tgctttttga	gcaggcagag	agcaacatga	agcgctacgg	caagatcctc	atgcaccaca	900
50	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcaa	gataggggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcgga	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
	acgagaagga	tccacagggtc	aaagagaagc	ttcacgcaga	ggcattttcc	ctgctgaaga	1200
55	gtggtcgctt	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	cctttacctt	tatgagcagg	ggaagctggt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtac	cggcagggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	acccctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgccca	cctcttctag	1500
60	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcag	gactacctgg	1560
	tccaaaaaact	acagaaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccctg	atccgcccag	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgccct	ggagttgccc	tcagtccact	1740
	tctgtgtgtg	ccactccttc	caccaacact	gctttgagag	ttactcgga	agtgtatgctg	1800
65	actgccccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gccagggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
	agaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
5	gtcccactct	catctaattg	cacagccctc	acaagactaa	agcggaactt	tttcttttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	cctctttaac	taggcaggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctggttt	c				
10	<210> 21						
	<211> 179						
	<212> DNA						
	<213> Human						
15	<400> 21						
	agggtgttaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
20	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210> 22						
	<211> 905						
	<212> DNA						
	<213> Human						
25	<400> 22						
	tttttttttt	ttctttaacc	gtgtggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaatgttcc	agttagaagg	aattcaaacg	gaatgccaa	gtccaagcca	ggctcaagaa	120
30	ataaaaagg	aggtttgag	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtggtgggaa	300
	tagggtcatt	aataactatg	aatatatctt	ttagaagggtg	accattttgc	actttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaagaagt	ggcgagaaag	420
35	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcatgcca	480
	aatctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttcaaaata	aactcgcaag	540
	gtctgaccag	ttcttggtta	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaattgcctc	tttcaaacat	tgggggaacc	agtagaaaaa	660
	ggcagggtct	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagt	720
40	cctgaagatg	gtaaccacag	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactcct	tgctgcagag	acaaagttag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaat	900
	gttga						
45	<210> 23						
	<211> 2134						
	<212> DNA						
	<213> Human						
50	<400> 23						
	ggctctcttct	ttcctttttt	tttttccaaa	agtggttctt	tatttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttaa	aagttttttt	120
	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcatttatta	ctaactatag	180
55	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctaccctc	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggaccctgt	tctacacacc	420
	tcatttttgt	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
60	agttacttct	ttacatccat	attcccaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tgagggtact	aaagtcattg	tgtctcctct	agctttttacc	agcatctaata	gcttcactgc	600
	tttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagttgt	tttttcttca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccattttg	720
	gttattttcac	gttgctgagc	ctttctctca	tggtgaacaa	tctgaagttt	taattctcgg	780
65	tgaataaat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaaa	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	cagggtcttag	900

5 taaaatctca cttttctcct acttttccatt tcccaacccc catgatacta agtatttgat 960
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttggtttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctcactaact atcctatcaa atttgcaact 1140
 ggaggtttac tctgatgatt caactccttt tctatctacc ccataaatcc cactttactg 1200
 atacacctca ctgggtactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttcctcactt tgcttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcatctctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
 10 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggctcgcaca aggtctgggt ctggctggct tcaactcctt tgcaactcgc gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaaggga ttgccacag 1740
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat ccctctggt tccgctgttt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatata caggttttgc actagtaact gatcctgata 2040
 20 tttttttaca agtagatcca tttccccgc aacaccaca ttatcaaac ttctttttgg 2100
 agtctatgat gcgatacaaa ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaactttt caaatatgag catcatatgt gtttaaggctg 180
 tatcatttta tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
 35 agttgttttt tactgtact aaatgttggc tactgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaaaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420
 ggtagtgatg cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540
 40 aaagctttgt ctaaaaattt ggccctaggaa tggtaacttc attttcagtt gccaaaggggt 600
 agaaaaataa tatgtgtgtt gttatgttta tgttaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttggg 840
 45 tctggaatgc attagttatg cctgttacca ttcccagaat ttcaggggca tctgtgggtt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttggtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcactctat ggaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 55 attataacctg tcacgttctt agttgcttca accattttat aaccattttt gtacatattt 1560
 tacttgaaaa tatttttaaat ggaattttta ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

	ttcattgaaa	tccttgctac	ttctcttcct	cctcaatgaa	agacacgaga	gacaaagagc	120
	acacaagctt	aagaaaaacg	agcaaggaag	agtatcttca	ttattctcat	tttctctgag	180
	ttggaaacaa	aaacatgaag	gactccaact	agaagacaga	tattttacatt	taaataagatt	240
5	agtgggaaaa	ctttaagagt	ttccacatat	tagttttcat	tttttgagtc	aagagactgc	300
	tcctttgtact	gggagacact	agtagtatat	gtttgtaatg	ttactttaaa	attatctttt	360
	tattttataa	ggcccataaa	tactggttaa	actctgttaa	aagtgggcct	tctatcttgg	420
	atggtttcac	tgccatcagc	catgctgata	tattagaaat	ggcatcccta	tctacttact	480
	ttaatgctta	aaattataca	taaaatgctt	tatttagaaa	acctacatga	tacagtgggtg	540
10	tcagccttgc	catgtatcag	tttcacttga	aatttgagac	caattaaatt	tcaactgttt	600
	aggggtgaga	aagagggtact	ggaaaaacatg	cagatgagga	tatcttttat	gtgcaacagt	660
	atccttttgca	tgggaggaga	gttactcttg	aaaggcaggc	agcttaagtg	gacaatgttt	720
	tgatatatagt	tgagaatttt	acgacacttt	taaaaattgt	gtaattgtta	aatgtccagt	780
	tttgctctgt	tttgctgtaa	gttttagtat	ttgttttcta	ggtggacctc	tgaaaaacaa	840
15	accagtatct	ggggagggtta	gatgtgtgtt	tcaggcttgg	agtgtatgag	tggttttgct	900
	tgtatttttc	tccagagatt	ttgaacttta	ataattgcgt	gtgtgttttt	ttttttttaa	960
	gtggctttgt	ttttttttct	caagtaaaat	tgtgaacata	tttcctttat	aggggcaggg	1020
	catgagtttag	ggagactgaa	gagtattgta	gactgtacat	gtgccttctt	aatgtgtttc	1080
	tcgacacatt	ttttttcagt	aacttgaaaa	ttcaaaaagg	acatttggtt	aggttactgt	1140
20	acatacatct	atgcataaat	ggcagcttgt	tttcttgagc	cactgtctaa	attttgtttt	1200
	tatagaaatt	ttttatactg	attggttcat	agatggtcag	ttttgtacac	agactgaaca	1260
	atacagcact	ttgccaaaaa	tgagtgtagc	attgtttaaa	cattgtgtgt	taacacctgt	1320
	tctttgtaat	tgggttgtgg	tgcattttgc	actacctgga	gttacagttt	tcaatctgtc	1380
	agtaaataaa	gtgtccttta	acttcaaaaa	aaaaaaaaaa			
25	<210>	26					
	<211>	689					
	<212>	DNA					
	<213>	Human					
30	<400>	26					
	aaacaaacaa	aaaaaaagtt	agtactgtat	atgtaaatac	tagctttttca	atgtgctata	60
	caacaataa	tagcacatcc	ttcctttttc	tctgtctcac	ctccttttagg	tgagtacttc	120
35	cttaaaataag	tgctaaacat	acataatacg	aacttgaaag	ctttggtttag	ccttgccctta	180
	ggtaatcagc	ctagttttaca	ctgtttccag	ggagtagttg	aattactata	aaccatttagc	240
	cactttgtctc	tgcaccattt	atcacaccag	gacagggctc	ctcaacctgg	gcgctactgt	300
	cattttggggc	caggtgattc	ttccttgcaa	gggtgtcct	gtacctgccc	gggcggccgc	360
	tcgaagcgtg	gtcgcggccg	aggtagtgaa	aggaccaagg	agctctggct	gccctcagga	420
40	attccaaatg	accgaaggaa	caaagcttca	gggtctgggg	tgtgtctctc	cactatttcag	480
	gaggtggctg	gaggtaacgc	agcttcattt	cgctccagtc	tttccagtat	ttaaagtgtg	540
	tgtaagatg	ctgcattaaa	tcaggcaggt	ctacaaaggc	atcccaagca	tcaaacatgt	600
	ctgtgatgaa	gtaatcaatg	aaacaccgga	acctccgacc	acctcctgaa	tagtggggaga	660
	cacaccaga	gcctgaagtt	tgtccttcg				
45	<210>	27					
	<211>	471					
	<212>	DNA					
	<213>	Human					
50	<400>	27					
	tcccagcggc	atgaagtttg	agattggcca	ggcctgtac	ctgggcttca	tctccttcgt	60
	ccctctcgct	cattggtggc	accctgtctt	gcctgtcctg	ccaggacgag	gcaccctaca	120
55	agccctaacc	caggcccccgc	ccagggccac	cacgaccact	gcaaacaccg	cacctgccta	180
	ccagccacca	gctgcctaca	aagacaatcg	ggccccctca	gtgacctcgg	ccaccacagc	240
	gggtacagge	tgaacgacta	cgtgtgagtc	cccacagcct	gcttctcccc	tgggctgctg	300
	tgggctgggt	cccggcgagg	ctgtcaatgg	aggcagggtg	tccagcacia	agtttacttc	360
	tgggcaattt	ttgtatccaa	ggaaataatg	tgaatgcgag	gaaatgtctt	tagagcacag	420
60	ggacagaggg	ggaaataaga	ggaggagaaa	gctctctata	ccaaagactg	a	
	<210>	28					
	<211>	929					
	<212>	DNA					
	<213>	Human					
65	<400>	28					

	ggtgaactca	gtgcattggg	ccaatgggtc	gacacaggct	ctgccagcca	caaccatcct	60
	gctgcttctg	acgggtttggc	tgctgggtggg	ctttccctc	actgtcattg	gaggcatcct	120
5	tgggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccggga	180
	gattccaccc	cagccctggg	acaagtctac	tgatcatccac	atgactgttg	gaggcttcct	240
	gcctttcagt	gccatctctg	tggagctgta	ctacatcttt	gccacagtat	ggggctcgga	300
	gcagtacact	ttgtacggca	tcctcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgcaactca	cctacttcca	gttgtctggg	gaggattacc	gctgggtggg	420
	gcgatctgtg	ctgagtgttg	gctccaccgg	cctcttcac	ttcctctact	cagttttcta	480
10	ttatgcccg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttcctcat	gctgggcacc	atctcctttt	tttcttccct	600
	aaagtccatc	cggatatatct	atgttaacct	caagatggac	tgagtctctg	atggcagaac	660
	tattgctgtt	ctctcccttt	cttcatgccc	tggtgaactc	tcctaccagc	ttctcttctg	720
	attgactgaa	ttgtgtgatg	gcattgttgt	cttccctttt	tccctttggg	cattccttcc	780
15	ccagagagg	cctggaaatt	ataaatctct	atcacataag	gattatata	ttgaactttt	840
	taagttgcct	ttagttttgg	tcctgatttt	tctttttaca	attaccaaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaaa	aaaaaaaaaa				
	<210>	29					
20	<211>	1775					
	<212>	DNA					
	<213>	Human					
	<400>	29					
25	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaaatgt	ccgaagggat	tttggccaac	60
	accagaaaaac	gccaatgtcc	taggaattcc	ctcccaaaat	gcttcccaaa	aaattactca	120
	ttgacaattc	aaattgcact	tggtggcg	cagcccgggc	ggccttcagt	ccgtgtgggg	180
30	cgcccgctg	gccttctcct	cgtaggactc	cccaaaactcg	ttcactctgc	gtttatccac	240
	aggataaagc	caccgctggg	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccgggtga	gacgtgggca	tggtgatgat	gaaggcaaa	acgtcatcaa	tgaaggtgtt	360
	gaaagccttg	taggtgaagg	ccttcagggg	cagatgtgcc	actgacttca	actttagatt	420
	cacaaagagc	tggggcagca	tgaagaggaa	accaaaggca	tagaccccg	tgacgaagct	480
	gttgattaac	caggagtacc	agctcttata	tttgatattc	aggagtgaat	agacagcacc	540
35	cccagacacag	agagggtaca	gcaggatga	caagtacttc	atggcctgag	tatcgtactc	600
	ctcggttttc	ctctcagatt	cgtgtgaagt	gccaaaactga	aattcgggca	tcaggcctct	660
	ccaaaaaata	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggctccaac	720
	accgcgcggg	accagcacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
	cacgggtgctg	aagcagcgcc	agagcactgc	cttgggtggac	atgccgatca	tgctcttctt	840
40	cttcttccag	aaactgatgt	cattttttaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaaag	aaggtcagcg	ccaggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tctttctctg	aaaaccggaa	ctgctgcagg	gagtacacgg	cgtcctgcat	1020
	gtggatccag	aagcgcagcc	gcccagtgta	gaccttgtcg	taggacacgg	tgagggcgag	1080
	ctcgggtggg	gagcgggtta	tgaccatcag	gtccttcacg	cggttgctga	gctggtcgat	1140
45	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtaccgatg	1200
	cacatcggca	ggcaggggag	acccgtcaaa	gacaaagtgt	tccgccatca	cgttcagcgc	1260
	cagccgcggg	cgccagtggt	acactggctc	atccagggca	ctcgtcggct	tcttctccgc	1320
	ctcgtatctgc	tgtgtatcag	actccccggg	gagcaggttg	atttcttctg	gcttggggac	1380
	catgtagggtg	gtcagaggac	tgaccagggtg	cacctgcttc	ccgtcgtgcc	acggcaggac	1440
50	cccagcgtga	tggaggaaga	tgtaggcata	cagcgtccca	ttgtttctcg	ttttcttttg	1500
	tacagaaaca	ttaactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccagggtcg	atgttgttct	cagcacccag	gtgggacctc	gtcgtgggtg	acacgctcag	1620
	ctgcagcttg	ggccgcgcg	ccaggtaggg	ctggatgcag	ttggcgtcgc	cggagcacgg	1680
55	gcgggtgtag	acgatgccgt	acatgaccca	gcagggtgtg	accacgtaga	ccacgaacac	1740
	gcccaccacc	aagctgggtga	aggagctgcg	gcccc			
	<210>	30					
	<211>	1546					
	<212>	DNA					
60	<213>	Human					
	<400>	30					
65	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgcta	60
	aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgaacca	ttcttttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tgttggttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tgttgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagtcc	aattaaaaca	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcacac	cttctaaaaac	tgggtacatta	600
	acctcaatac	cagttacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccc	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	ttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgaact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaattttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
20	actttccctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatataa	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30							
	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcacaaa	aggtgtgctg	60
35	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgcta	cggatatttc	tgtttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
40	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactattttc	catgcattaa	atatgataaa	ataatctatc	540
	actgcacatc	ggtcttgtaa	aaagggaagt	tgaatacaga	gccacaaca	ctaaaattgt	600
	ttttctagct	gcaaaagtata	gcatcatcaa	cacagacacg	atttggaact	cctgacagtg	660
45	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tatttgtcac	caccgtcccg				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattccccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttgggtgcc	cagaaaaatc	tgctcctttt	ggtaccaaac	120
	ctgaggtcct	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttgcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttataaaa	ttataaaaaa	360
60	aaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcaacta	ttccaggaca	420
	cgctggcatt	tggactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtccctt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
65	tgagattgtg	cacaaaaaatt	aggtcatgcc	ttcagtgctc	tggtctttaa	acctaccett	720
	tgacaatcag	gtgctaataa	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccgaaa	1080
	aaatctgtcc	tttttggtac	caaacctgag	gtcttttgga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactctg	tgcaaaactct	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgtctt	cattttttaag	tataaaagact	tagaaaacta	gaataatgct	1260
10	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaacctgtg	1320
	atttaaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttccta	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	agggtattat	atatataaat	1560
15	acatatatac	ctttgttaacc	tttatactgt	aaataaaaaa	gttgctttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtataag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggagga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	taattattga	tactcctggg	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	aggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggatcacac	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtagcgatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttgagcccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgactct	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ctttgtgacc	tacctctgca	catactgggtg	atggcatggg	aagtctgac	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaagga	gatacaatca	ttgttcctgg	agtagaaggg	1140
	cccatgttaa	ctcagattcg	aggctcctg	ttacctctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
45	aaagacctgg	agaaaacatt	ggctggttta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccctat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agttacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtgga	1800
	gcaggtcagg	tgaaacaggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgtagacatc	1860
55	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagttttgtg	taaaaataga	accatccctc	ggtgagtcac	ccaaaatggt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtcatttga	tgactcaaaa	2040
	gactgggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcattctaatt	ttttcacatg	gagcaggaac	tggaagtaaa	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tgggaaggag	aaaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	gggttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgttttaaa	tttgcccttc	2400
	cccaaatttg	gatttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
	gtactgcagt	atttgattaa	aaaaaaaata	gcagattttg	tgattcttgg	gacttttttg	2520
65	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

	agctgctttg	tgtgaaacca	tgggtgtaaaa	gcacagctgg	ctgcttttta	ctgcttgtgt	2700
	agtcacgagt	ccatttgaat	catcacaatt	ctaaaccaa	ctaccaataa	agaaaacaga	2760
	catccaccag	taagcaagct	ctgttaggct	tccatgggta	gtggtagctt	ctctcccaca	2820
	agttgtcctc	ctaggacaag	gaattatctt	aacaaactaa	actatccatc	acactacctt	2880
5	gggtatgccag	cacctgggta	acagtaggag	attttatata	ttaatctgat	ctgtttaatc	2940
	tgatcgggtt	agtagagatt	ttatacat				
	<210>	34					
	<211>	6011					
10	<212>	DNA					
	<213>	Human					
	<400>	34					
15							
	acggggcgcc	ggacgacccg	cacatcttat	cctccacgcc	ccactcgcac	tgggagcggg	60
	accgcccccg	actccccctc	gggcccggca	ctcgaggagt	gaggagagag	gccgccggcc	120
20	cggcttgagc	cgagcgcagc	accccccgcg	cccccgccca	gaagtttggg	tgaaccgggc	180
	tgccgggaga	aacttttttc	ttttttcccc	ctctcccggg	agagtctctg	gaggaggagg	240
	ggaactcccc	cggcccaagg	ctcgtgggct	cggggtcgcg	cggccgcaga	aggggcgggg	300
	tccgcccgcg	aggggaggcg	ccccgggga	cccagagggg	gggtgaggac	cgcgggctgc	360
	tgggtgcggc	gcggcagcgt	gtgccccgcg	caggggaggc	gccgcccgcg	tcccggcccc	420
25	gctgcgagga	ggaggcggcg	gcggcgcagg	aggatgtact	tgggtggcggg	ggacaggggg	480
	ttggccggct	gcgggcacct	cctgggtctcg	ctgtggggc	tgctgctgct	gccggcgcgc	540
	tccggcaccc	gggcgctggt	ctgcctgccc	tgtgacgagt	ccaagtgcga	ggagcccagg	600
	aaccgcccgg	ggagcatcgt	gcagggcgtc	tgcggtgct	gctacacgtg	cgccagccag	660
	gggaacgaga	gctcggcggg	caccttcggg	atttacggaa	cctgcgaccg	ggggctgcgt	720
30	tgtgtcatcc	gcccccgct	caatggcgac	tccctcaccg	agtacgaagc	gggcgtttgc	780
	gaagatgaga	actggactga	tgaccaactg	cttggtttta	aaccatgcaa	tgaaaacctt	840
	attgctggct	gcaatataat	caatgggaaa	tgtgaatgta	acaccattcg	aacctgcagc	900
	aatccctttg	agtttccaa	tcaggatatg	tgcccttcag	ctttaagag	aattgaagaa	960
	gagaagccag	attgctccaa	ggcccgcgtg	gaagtccagt	tctctccacg	ttgtcctgaa	1020
35	gattctgttc	tgatcgaggg	ttatgtcctt	cctggggagt	gctgtccctt	accagccgc	1080
	tgctgtgca	acccgcgagg	ctgtctgcgc	aaagtctgcc	agccgggaaa	cctgaacata	1140
	ctagtgtcaa	aagcctcagg	gaagccggga	gagtgtgtg	acctctatga	gtgcaaacca	1200
	gttttcggcg	tggactgcag	gactgtggaa	tgccctactg	ttcagcagac	cgcgtgtccc	1260
40	ccggacagct	atgaaactca	agtcagacta	actgcagatg	gttgtgttac	tttgccaaca	1320
	agatgcgagt	gtctctctcg	cttatgtggt	ttccccgtgt	gtgaggtggg	atccactccc	1380
	cgcatagtct	ctcgtggcga	tgggacacct	ggaaagtgt	gtgatgtctt	tgaatgtgtt	1440
	aatgatataa	agccagcctg	cgtatttaac	aatgtggaat	attatgatgg	agacatgttt	1500
	cgaatggaca	actgtcgggt	ctgtcgatgc	caaggggggc	ttgccatctg	cttcaccgcc	1560
	cagtgtgtgtg	agataaactg	cgagaggtag	tacgtgcccc	aaggagagtg	ctgcccagtg	1620
45	tgtgaagatc	cagtgtatcc	ttttaataat	cccgtgtggc	gctatgccaa	tggcctgatc	1680
	cttgcccacg	gagaccgggt	gcgggaagac	gactgcacat	tctgccagtg	cgtcaacggt	1740
	gaacgccact	gcgttgcgac	cgtctgcgga	cagacctgca	caaaccctgt	gaaagtgcct	1800
	ggggagtgtt	gccctgtgtg	cgaagaacca	accatcatca	cagttgatcc	acctgcattg	1860
	ggggagtatt	caaactgcac	tctgacacgg	aaggactgca	ttaatggttt	caaacgcgat	1920
50	cacaatggtt	gtcggacctg	tcagtgcata	aacaccagg	aactatgttc	agaacgtaaa	1980
	caaggctgca	ccttgaactg	tcccttcggt	ttccttactg	atgccccaaa	ctgtgagatc	2040
	tgtgagtgtc	gccccaggcc	caagaagtgc	agaccataaa	tctgtgacaa	gtattgtcca	2100
	cttggaattgc	tgaagaataa	gcacggctgt	gacatctgtc	gctgtaagaa	atgtccagag	2160
	ctctcatgca	gtaagatctg	ccccttgggt	ttccagcagg	acagtcacgg	ctgtcttatc	2220
55	tgcaagtgca	gagaggcctc	tgtctcagct	gggccaccca	tcctgtcggg	cacttgtctc	2280
	accgtggatg	gtcatcatca	taaaaatgag	gagagctggc	acgatgggtg	ccgggaatgc	2340
	tactgtctca	atggacggga	aatgtgtgcc	ctgatcacct	gcccgggtgc	tgccgtgggc	2400
	aacccaccca	ttcaccttgg	acagtgtctg	ccatcatgtg	cagatgactt	tgtgggtcag	2460
	aagccagagc	tcagtactcc	ctccatttgc	cacgcccctg	gaggagaata	ctttgtggaa	2520
60	ggagaaacgt	ggaacattga	ctcctgtact	cagtgcacct	gccacagcgg	acgggtgtct	2580
	tgtgagacag	aggtgtgccc	accgtgtgct	tgccagaacc	cctcacgcac	ccaggattcc	2640
	tgctgcccac	agtgtacaga	tcaacctttt	cggccttcct	tgccccgcaa	taacagcgta	2700
	cctaattact	gcaaaaatga	tgaaggggat	atattcctgg	cagctgagtc	ctggaagcct	2760
	gacgtttgtg	ccagctgcac	ctgcattgat	agcgtaatta	gctgtttctc	tgagtctctg	2820
65	acttctgtat	cctgtgaaag	acctgtctgt	agaaaaggcc	agtgtgttcc	ctactgcata	2880
	aaagacacaa	ttccaaagaa	gggtgtgtgc	cacttcagtg	ggaaggccta	tgccgacgag	2940

	gagcgggtggg	accttgacag	ctgcacccac	tgtactgccc	tgcagggcca	gaccctctgc	3000
	tgcaccgtca	gctgcccccc	tctgcccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagagggtga	cctggagggt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcgctccatc	tccttagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtgggtcc	cataattata	3300
	tgcctctcta	ttataatagc	attcctattc	atcaatcaga	agaaacagt	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
	gactgcaaga	aaggaaccag	agtccagggt	gacagttccc	agagaatgct	aagaattgca	3480
10	gaaccagatg	caagattcag	tggcttctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaact	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	aaagcattcc	cacttttctc	caagataact	gaccaagtgt	tttcttagaa	3780
15	ccaaagtitt	taaaagtgtc	aagatatatt	tgctgtgaag	atagctgtag	agatatttgg	3840
	gggtggggaca	gtgagtttgg	atggggaaag	gggtgggagg	gtgggtgttg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggt	aacataaaag	cagttcagtg	gcccagagggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctggttgctg	caaagctcag	gcctgaatga	4020
	gcaggaataa	aaaaaggcct	tgcgaccacg	ctgccataac	caccttagaa	ctaccagacg	4080
20	agcacatcag	aaccttttga	cagccatccc	aggtctaaag	ccacaagttt	cttttctata	4140
	cagtcacaac	tgcaagtagg	agtgaagga	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gctttttatt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
	atgtgagcac	tggagctttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
25	gaacaccagg	catttccagg	ggctatat	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaaag	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgtttgg	ggattctttt	tccttattat	atactgattc	tacaaaaatg	aaactacttc	4560
	attttaattg	tatatatttc	aagcaccttt	gttgaagctc	aaaaaaaatg	atgcctctgt	4620
	aaacttttag	aattatagga	gtatttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
30	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggg	4980
35	attcctttat	taaaaatctc	ctcatttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcctat	ctgcatcact	aatcagctcc	tggatttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttgttg	tgaatgcct	caaataatac	tgactgtata	ctatagtggg	aacttttcaa	5220
	acagccctta	gcacttttat	actaattaac	ccatttgctg	attgagtttt	cttttaaaaa	5280
40	tgcttggtgt	gaaagacaca	gatacccagt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaa	gaactttcaa	gtattgttgt	aaataactgg	acagagggtg	ctgaacttta	5400
	aaaaaaaatta	atttattatt	ataatgacct	aatttattaa	tctgaagatt	aacctttttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaaggaa	5520
	aaaaagattt	attatcaagg	ggcaatattt	ttatcttttc	caaaataaat	ttgttaataa	5580
45	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	tttgtttttt	5700
	caatcatggc	caatattatga	aaatactaac	aggatatag	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttactttggg	5820
	tcctgtgttg	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaat	agatatatgg	5880
50	cacttgaggt	gcacataggt	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcglllvsl	lgllllpars	gtralvclpc	deskceprn	rpgsivqgvc	60
	gccytcasgg	nescgggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
65	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkriece	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpge	240

5 ccdlyeckpv fgvdortvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmdfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcwatvcgq tctnrvkvpg eccpvceep t iitvdppacg elsnctlttrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgr ltdaqnceic ecrprpkcr 540
 piicdkycpl gllknkhgdc icrckkcpel scskicplgr qqdshgcllc kreasasag 600
 ppilsgtclt vdghhkhnee shwdgcrecy clngremcal itcpvpacgn ptihpggqccp 660
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
 qnpsrtqdsq cpqctdqpfr pslsrnnsnp nyckndegdi flaaeswkp vctscicids 780
 10 viscfscscp svscerpvlr kgqccpycik dtipkkvvh fsgkayadee rwdldscthc 840
 yclgggtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrlh psedssldsi asvvvpiiic lsiiiaflfi 960
 ngkkqwipll cwyrtptkps slnnqlvsvd ckggrtrvqd ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35
 <211> 716
 <212> DNA
 20 <213> Human

<400> 35
 25 gcagtagctg gagtgcctg cagggggaaa gogaaccggg cctgaagtc cggggcagtc 60
 acccggggct cctgggccc tctgccggg tggggctgag cagcgatcct gctttgtccc 120
 agaagtcacg agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaagcatga agagtgggct ccacgtgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctctgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggt ttctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt ctttaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36
 <211> 395
 40 <212> DNA
 <213> Human

<400> 36
 45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatat ttttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggttaacaa tgtcatttta caaatgtta aaacccta 300
 50 tgcagttcct tttttaaat attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37
 <211> 134
 55 <212> DNA
 <213> Human

<400> 37
 60 ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
 aaggacacc gtgt

<210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

```

5  aagcctgttg  tcatggggga  ggtggtggcg  cttggtggcc  actggcggcc  gaggtagagg  60
   cagtggcgct  tgagttggtc  gggggcagcg  gcagatttga  ggcttaagca  acttcttcg  120
   ggaagagtg  ccagtgcagc  cactgttaca  attcaagatc  ttgatctata  tccatagatt  180
   ggaatattgg  tgggccagca  atcctcagac  gcctcactta  ggacaaatga  ggaaactgag  240
   gcttggtgaa  gttacgaaac  ttgtccaaaa  tcacacaact  tgtaaagggc  acagccaaga  300
10  ttcagagcca  ggctgtaaaa  attaaaatga  acaaattacg  gcaaagtttt  aggagaaaga  360
   aggatgttta  tgttccagag  gccagtcgtc  cacatcagtg  gcagacagat  gaagaaggcg  420
   ttcgcaccgg  aaaatgtagc  ttcccggtta  agtaccttgg  ccatgtagaa  gttgatgaat  480
   caagaggaat  gcacatctgt  gaagatgctg  taaaaagatt  gaaagctgaa  aggaagttct  540
   tcaaaggctt  ctttgaaaaa  actggaaaga  aagcagttaa  agcagtttct  gtgggtctaa  600
15  gcagatggac  tcagaggttg  tggatgaaaa  actaaggacc  tcat

```

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

```

25  ctttttgttt  gggttttcca  atgtagatgt  ctcagtgaaa  tgtgcagata  tactttgttc  60
   cttatatggt  caccagtgtt  aattatggac  aaatacatta  aaacaagggt  tcctggccca  120
   gcctcccatc  taatctcttt  gatactcttg  gaatctaagt  ctgaggagcg  atttctgaat  180
   tagccagtgt  tgtaccaact  ttctgttagg  aattgtatta  gaataacctt  tctttttcag  240
   acctgctcag  tgagacatct  tggggaatga  agtaggaaaa  tagacatttg  gtggaaaaac  300
   agcaaaatga  gaacattaaa  aagactcatt  caagtatgag  tataaagggc  atggaaattc  360
30  tgggtcctttg  agcaaaatga  gaagaaaaaa  ttctgctcag  cagtattcac  tgtgttaaga  420
   ttttttgttt  tttacacgaa  tggaaaaatg  atgtgtaagt  ggtatagatt  ttaatcagct  480
   aacagtcact  ccagagattt  tgatcagcac  caattcctat  agtagtaagt  atttaaaagt  540
   taagaaatac  tactacattt  aacattataa  agtagagttc  tggacataac  tgaaaattag  600
   atgtttgctt  caatagaaat  ttgttcccat  ttgtattttc  aacaaaatta  tcggaac

```

35

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

```

45  acaattttta  aataactagc  aattaatcac  agcatatcag  gaaaaagtac  acagtgagtt  60
   ctggttagtt  tttgtaggct  cattatgggt  agggctcgta  agatgtatat  aagaacctac  120
   ctatcatgct  gtatgtatca  ctcatccat  tttcatgttc  catgcatact  cgggcatcat  180
   gctaatatgt  atccttttaa  gcactctcaa  ggaacaaaa  gggcctttta  tttttataaa  240
   ggtaaaaaaa  attcccaaaa  tattttgcac  tgaatgtacc  aaaggtgaag  ggacattaca  300
   atatgactaa  cagcaactcc  atcacttgag  aagtataata  gaaaatagct  tctaaatcaa  360
   acttccttca  cagtgcctg  tctaccacta  caaggactgt  gcatctaagt  aataattttt  420
   taagattcac  tatatgtgat  agtatgatat  gcatttattt  aaaatgcatt  agactctctt  480
   ccatccatca  aatactttac  aggatggcat  ttaatacaga  tatttcgtat  ttccccact  540
   gctttttatt  tgtacagcat  cattaaacac  taagctcagt  taaggagcca  tcagcaacac  600
   tgaagagatc  agtagtaaga  attccatttt  cctcatcag  tgaagacacc  acaaattgaa  660
   actcagaact  atattttctaa  gcctgcattt  tcatgatgc  ataattttct  tagtaattat  720
55  aagagacagt  ttttctatgg  catctccaaa  actgcatgac  atcactagtc  ttacttctgc  780
   ttaattttat  gagaagggtat  tcttcatttt  aattgctttt  gggattactc  cacatctttg  840
   tttatttctt  gactaatcag  attttcaata  gagtgaagtt  aaattggggg  tcataaaagc  900
   attggattga  catatgggtt  gccagcctat  gggtttacag  gcattgccca  aacatttctt  960
   tgagatctat  atttataagc  agccatggaa  ttcctattat  gggatgttgg  caatcttaca  1020
60  tttttatagag  gtcatatgca  tagttttcat  aggtgttttg  taagaactga  ttgctctcct  1080
   gtgagtttaag  ctatgtttac  tactgggacc  ctcaagagga  ataccactta  tgttacactc  1140
   ctgcactaaa  ggcacgtact  gcagtgtgaa  gaaatgttct  gaaaaagggt  tatagaaatc  1200
   tggaaataag  aaaggaagag  ctctctgtat  tctataattg  gaagagaaaa  aaagaaaaac  1260
   ttttaactgg  aaatgttagt  ttgtacttat  tgatcatgaa  tacaagtata  tatttaattt  1320
65  tgaaaaaa

```

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
 tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120
 taacccccgg ctatcagttc ggatgggttc caccctcctt gctgtaggat ggaagcagcc 180
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
 tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
 tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360
 15 aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
 ggaggaggga ggagctggta gggagatgct ggctttacct aaggctcga aacaaggagg 480
 gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
 tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
 gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
 20 cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780
 aatagtctac ggccatacca ccctgaacgt gcctaacttc gtaagctaag cagggtcagg 840
 cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttag 900
 actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
 tgaagtagcg atttgggtgtg aaaaaaa

25

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

35 cggacgggtg ggcggacgcg tgggtgcagg agcaggggcg ctgccgactg ccccaaccaa 60
 ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
 ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
 tcaggggatg tttacctggt gctcgggaag ggaggggaa gggccgggga gggggcacgg 240
 caggcgtgtg gcagccacac gcaggcggcc agggcgccca gggacccaaa gcaggatgac 300
 cagccacctc cagcccaactg cctccccga atgcatttgg aaccaaaagtc taaactgagc 360
 40 tcgcagcccc cgcgccctcc ctccgcctcc catcccgtt agcgtctctg acagatggac 420
 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480
 gagattgctg gaaaccaagt caggccaggt gggcggacaa aaggggccagg tgcggcctgg 540
 ggggaacgga tgctccgagg actggactgt tttttcaca catcgttgcc gcagcgggtg 600
 gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
 tgaattaatt cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
 45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
 tcgcaggacc aagggggcgg ggactgctgg ctcacgcccc gctgtgtcct ccctcccctc 840
 ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtgg 900
 ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

50

<210> 43
 <211> 536
 <212> DNA
 <213> Human

55

<400> 43

60 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
 cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
 agtgtagctt gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
 ttgggaacct agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
 tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
 cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
 attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420
 ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480
 65 aggggtggtt ccccggcacc tggacctgga caggtagggg tccgtgggta accagt

<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

10 ggggagggac gagtatggaa ccctgaagggt agcaagtcca ggcactggcc tgaccatccg 60
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atcccctctg gaggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tgggccatt 360
catggcagggt tctggggtca aagctgaact gggagagaa gagatacaga gctaccatgt 420
15 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctctccagt cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtgggtt gggctagtgt ggtttgaatt taggggccga 660
20 tgagcttggg tacgtgagca ggggtttaag ttagggtctg cctgtatttc tgggtcccctt 720
ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggt 840
gccagtgac ctgggggagc ctgggtgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
25 gatttggctg gtagagcctt cttagaggttc agaattattg cttcaggatc agctgggggt 1020
atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca gggatgattt agatctggaa cccccaagt 1140
aggctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaaatg 1200
aaagagtgc cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
30 gaagggtgct ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
ctgggtccct tgtagcacag gagactgggg ctaagggcc cctccaggga agggacacca 1380
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccaggag 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtctg 1560
35 cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgcttcctg cattcatctg 1620
caaaaaaaaa

<210> 45
<211> 169
<212> DNA
<213> Human

40

<400> 45

45 tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggt ttatgatctt cagtctgatt ccagtgtctc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttgaaga cttagttga

<210> 46
<211> 769
<212> DNA
<213> Human

50

<400> 46

55 tgcaggatcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtga 60
atthgtcgct ttcacttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120
acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataga 240
aagggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcataata tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
65 ttgatataatgtgtacaagta gtacctctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
<211> 2529
5 <212> DNA
<213> Human

<400> 47

10 ttttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120
tcaggacctg gtccctagtc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtgtgta gcttgccgag 240
ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
15 gccttactta gctcctggca gaggtgtgag ggggacctac gaggttcaaa atcaaatggc 360
atgttgccag cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcc ctctccctcc 540
actagtggg gccactgcac tgaggggggg cccaccaatt ctctctagag aagagacact 600
20 ccagaggccc ctgcaacttt gcggatttcc agaagggtgat aaaaagagca ctcttgagt 660
ggtgcccagg aatgttttaa atctatcagg cactatata agctggtggg ttcttctac 720
caagtggatt cggcatatga accacctact caatacttta tttttgtct gtttaaacac 780
tgaactctgg tgttgacagg taaaaaggag aagagatggg gactgtgaag aggggagggc 840
ttcctctatc ttccctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
25 gcaatagatg gggcttccca ccatttgttg gttattgctg gggttagcca ggagcagtg 960
ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttgggtct 1020
ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
aggatgaacag tctacactgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
30 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200
gaggggaagc cacacaatat cattgtgctg gggctcccca aggcctgcc acctggcttt 1260
acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
caaggagttt tcagggaact ctatcaagcc atacaaaat cagggtcaca tgtgggtttc 1380
ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcct 1440
gcagttgggc tgacctgaca aagccccagc tttcctgttg caggttctgg gagaggatgc 1500
35 attcaagctt ctgcagccta ggggacagg ctgctgttcc agttattact gcctcggagc 1560
tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
cttcggcagc attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
agggagaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
ggggagtggt gagggggaag aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100
45 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
gcagaactgg ctgaacaag atttcatggg gtcacccatg agagatgact caatgccaa 2220
gcctgaagtt atagagtgtt tacagcgggt gcgattttca ggggtcatcg ccaactgggt 2280
tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atccactga 2340
ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cactgcacca 2400
50 gtccagagcc ctgccacgga tgtacgcagg agccagcat taggcaatca ggagccagaa 2460
catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
gggggtgtcc

<210> 48
55 <211> 1553
<212> DNA
<213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
ttcatatata tatatacata catatataaa ggaacaatt tgcaaattha cacacctgac 120
aaaaccatata atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
ctagccaggc cgtttttcca tccctaagta ccattctctc atttggggccc ttctagggtt 240
65 ggggccctga ccttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

	ccatcaagag	ggctatggga	gccaagtga	cacgggggat	tgaggcta	tcacctga	420
	tcgaaaacag	cgcccagctt	cctcaccgca	ggcacgcgtc	ttttcttttt	ttttcctcga	480
	gacggagtct	cgctgtgttg	cccaggctgg	agtgcagtgg	cacgggtctcg	gctcactgca	540
	agctccacct	cctggattca	taccattctc	ctgcttcagc	cttccgagta	gctgggacta	600
5	taggtgccaa	ccactacgcc	tagctaattt	ttttttgtat	tttttagtaga	gacagggttt	660
	caccgtgtta	gccaggatgg	tctcgtctcg	actttgtgat	ccgcccgcct	cggcctccca	720
	aagtgcctgg	attacaggcg	tgagccacca	cacctggccc	cggcacgtat	cttttaagga	780
	atgacaccag	ttcctggcct	ctgaccaaag	aaaaaatgtc	acaggagact	ttgaagaggc	840
	agacaggagg	gtgggtggcag	caacactgca	gtgcttctg	gatgctgctg	gggtgctctc	900
10	cggagcgggt	gtgaacagcg	cacttcaaca	tgagcaggcg	cctggctccg	gtgtgtctct	960
	acttcagtgg	tgcacctgga	tggtggaagc	cagccttttg	ggcaggaaac	cagctcagag	1020
	aggctaccca	gctcagctgc	tggcaggagc	caggtattta	cagccataat	gtgtgtaaa	1080
	aaaaaacacg	ttctgcaaga	aactctccta	cccgtctggg	agactggggc	tccttgcttg	1140
	ggatgagcct	cactcaacgt	ggagatggtg	gtggactggg	ccctgaaaag	cgggccttgc	1200
15	agggccaagt	gaggtcctca	ggtcctaac	ccagtggccc	tctgaaaggg	gggtgagcag	1260
	cgaggggagc	aggaggcttc	tctctagtcc	ctttggaggc	tttggtgag	agaagagtga	1320
	gcagggagct	gggaatggtc	caggcaggga	agggagctga	agtgattcgg	ggctaattgcc	1380
	tcagatcgat	gtatttctct	ccctggctct	ccggagccct	cttgtcaccg	ctgctgcctt	1440
	gcaggaggcc	catctcttct	gggagcttat	ctgacttaac	ttcaactaca	agttcgctct	1500
20	tacgagaccg	ggggtagcgt	gatctcctgc	ttccctgagc	gcctgcacgg	cag	
	<210>	49					
	<211>	921					
	<212>	DNA					
25	<213>	Human					
	<400>	49					
	ctgtggtccc	agctactcag	gaggtcgagg	cgggaggatt	gcttgagccc	aggagtggga	60
30	tggtgcagtg	agccaagatc	gcaccattgc	cctccactct	gggccacgga	gcaataccct	120
	gtctcagaaa	acaaacaaca	aaaagcagaa	acgctgaagg	ggtcgggtta	cgggaaaacc	180
	gcctgtcaga	acacttggct	actcctaccc	cagatcagtg	gacctgggaa	tgagggttgg	240
	tcccgggagg	cttttctcca	agctgttgcc	accagacccg	ccatgggaa	cctggccaca	300
	gaagcctccc	ggggagttag	ccagagcctg	gaccgctgtg	ctgatgtgtc	tgggggtggag	360
35	ggaggggtgg	gagtggtcaa	gggtgtgtgt	gtgcccgggg	ggtgttcatt	ggcaagcatg	420
	tgcgtgcctg	tgtgtgtcgg	tgccctcccc	ctgcagccgt	cgggtggtatc	tccctccagc	480
	cccttcgccca	ccttctgagc	attgtctgtc	cacgtgagac	tgcccagaga	cagcagagct	540
	ccagctgggt	ttaaggggag	acctttccct	ggacctgggg	gtctgcgcgt	atctcatgac	600
	cagggtgctaa	atgacccgac	atgcatacc	tgcttttcga	tgaccaacct	ccctgtcccc	660
40	gtcccgtgta	cctgcccccg	tggcgtctca	cgggtgatgcc	tgctcctgac	attggtgttc	720
	actgtagcaa	actacattct	ggatgggaat	tttcatgtac	atgtgtggca	tgtggaaaat	780
	ttcaataaaa	atggacttga	tttagaaagc	caaaaagctg	tgtggtcctt	ccagcacgga	840
	tactttgacc	tcttgccctac	aaccctttcc	ttgggtccga	ggctggtagc	tttgttccat	900
45	tcagatgggt	gggggcgggt	g				
	<210>	50					
	<211>	338					
	<212>	DNA					
	<213>	Human					
50	<400>	50					
	atgatctatc	tagatgccct	accgtaaaat	caaaacacaa	aaccctactg	actcattccc	60
	tccccttcag	atattacccc	atttctctac	ttcccattgt	agccaaactt	tccaaaaatt	120
55	catgtttctgt	cttcatttcc	tcatgttcaa	cccacctgtg	cttagctacc	acccctcagt	180
	aacgacctag	cctgggtaga	aacaaatgtc	agcatgatac	catactcaat	gatocttctg	240
	cactgttgtc	attgtcatca	ttccatggcc	ttactttccc	tctcagcgcc	atttcttaca	300
	gtaagaaact	ttctttcttg	aattcttggt	tctcttgg			
60	<210>	51					
	<211>	1191					
	<212>	DNA					
	<213>	Human					
65	<400>	51					

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccgggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa aactcagtg tgttggtctt ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaaca gttaataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420
 ccccgctcct ctcccccagg aggtcctctg atttatggta gctttggact tgcttccccg 480
 10 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540
 ccatcacaga taaaagaaaa atacaggaaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacaggaaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
 aaaaagctga atcgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140
 20 atgggcaaaa gtccagtgtt ttcagtaaag tgctaatacac aagttggagg t

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30 aacagggact ctcactctat caaccccagg ctggagtccg gtgcgcccac cctggctccc 60
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180
 cgcttctgt ccaggccggc atcatatact ttaaactcatg cccagatgac tttataacct 240
 aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcatttttgc 300
 35 accaacctta atgctatgta aatagttggt atactgttgc ttaacaacag tatgacaatt 360
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420
 ttctcagtggt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagt aaagttatgg tacagtggaa agagttagttg aaaacataaa catttggacc 600
 40 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggttc 660
 tgctactaat tagctataat ctttgacaaa attacatcac ctttgagtct cagttgcctc 720
 acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780
 actctgttat gctgaggaa aaattcacat tgtgttaact gtatgagtca aactgaaaat 840
 gattattaaa gtgggaaaaa gccaattgct tctcttagaa agctcaacta aatttgagaa 900
 45 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctattttatt 960
 agagatgggg tctcactctg tcaaccagac tggagtacag tggcacaatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtgate ctctgcctc tgccctcaga gtactgcga 1080
 ctatgggcat gtgccaccac gcctggctaa catttgattt gacctattta tttattgtga 1140
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga cttttatttt 60
 tatgcctttc ttcctatgtg ttttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctgactg tgcaggagtc caggaggcct ctacaaatgc 180
 agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttcctcca 240
 ggaatgtgcc atttcagatg cacagcaccc atgcagaaaa gctggaaattt tccttggaaac 300
 cgactgtgat agaggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360
 gtttcgcttg tgcccaggct gagtgcacat cgtgatctca ctactgcaa ttocacctcc 420
 aggttcaagc attctcctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaa 540
 cccaacctca gtgatctgcc acctcagcct cctaagtggt ggattacagg atgagccacc 600

5	cgaccggcca	ctactgtott	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaagtaa	tttcaaagag	780
	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aatcagtta	840
	ttaatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtgc	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccacccg				
10	<210> 54						
	<211> 250						
	<212> DNA						
	<213> Human						
15	<400> 54						
	catttcccca	ttggtcctga	tggtgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	taggggaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtgggtggag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
20	aaagggcatt	cttttaggaac	tgcatctggt	aaccacacac	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210> 55						
	<211> 2270						
25	<212> DNA						
	<213> Human						
	<400> 55						
30	gcgcccccca	gcagcgcccc	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggccccgcgc	ccgcccagcc	ctcgctctcc	tgcccaccgg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgacgcgcct	gtccgctgca	caccagcttg	ttggcgctct	cgtcgcccgc	180
	ctcgccccgc	gctaactctg	cgcgccacaa	tgagctcccc	catcgccagg	gcgctcgcc	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tggcgctctc	cacctgcccc	gctgcctgcc	300
35	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggctcgg	gacggctgcg	360
	gctgctgtaa	ggctgcgccc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgcgaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gcccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttctctgtg	tcccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtg	660
	tcaaagttac	cgggcagtgc	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttggca	aggagctggg	attcgatgcc	tccgaggtgg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtccc	840
	ctgttttttg	aatggagcct	cgcatcctat	acaacccttt	acaaggccag	aatgtattg	900
45	ttcaaaacac	ttcatggtcc	cagtgtctca	agacctgtgg	aactggtatc	tccacacgag	960
	ttaccaatga	caaccctgag	tgccgccttg	tgaaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatcccccca	accagtcagg	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttctctg	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
50	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
	agtcctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcgttt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaaa	gagtgtcaga	atcagaatca	tgagagaaaat	gggcgggggt	1440
	gggtgtgggtg	atgggactca	ttgtagaag	gaagccttgc	tcattcttga	ggagcattaa	1500
55	gggtatttoga	aactgccaag	gggtgctggtg	cggtatggaca	ctaattgcagc	cacgatttga	1560
	gaatactttg	cttcatagta	ttggagcaca	tggtactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgtttttc	gtttgtaaat	tatttgctaa	gcataatttc	tctaggcttt	1680
	tttctttttg	gggttctaca	gtcgtaaaag	agataataag	attagtttga	cagtttaaag	1740
	cttttattcg	tcctttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
60	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
	ggtgttttaa	gactgaatgt	tttatttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	ttgaatactg	gaataatttg	ttaattttat	tatttttata	ttcagtgaag	agattttatt	1980
	tatggaatta	accatttaat	aaagaaatat	ttacctata	tctgagtgtg	tgccattcgg	2040
	tatttttaga	ggtgctccaa	agtcatttag	aacaacctag	ctcagctact	caattattca	2100
65	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
	ttataccttc	agttagagaaa	agtctttgca	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

5 aaaatgtaaa cttcacctag ttcattctt ccaaatecca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtatata aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaaccctaa taaaccaagt acaaaaaata ttcataataa 180
 gttggttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagattttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttaccc tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgogaattta gtagtaatag cggccgc